Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DNTH vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DNTH Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 3–4 Matrix Metrics)

DNTH Overall Winner 6-Pillar Tally: DNTH 4 – 0 RAPT (2 Tie) Matrix Metrics: DNTH 3 – 4 RAPT

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.75 (N/M Forward P/E, -8683.9% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DNTH vs RAPT
DNTH NASDAQ Head-to-Head Winner
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.75
-3.33% 1D
Market Cap $5.2B
TTM Revenue $2.7M
Forward P/E N/M
Beta / 30D Vol 1.04β · 41% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.0 · SMA20: $83.96 · SMA50: $88.06
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (DNTH 4 – 0 RAPT)

Columns: Metric · DNTH · RAPT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DNTH
Revenue Growth (YoY) +205.6% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.7M N/A
Market Cap $5.2B $1.7B
3. Profitability & Quality DNTH
Gross Margin 100.0% N/A
Operating Margin -8683.9% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -22.6% -85.4%
4. Balance Sheet & Cash Flow DNTH
Cash Generation (TTM) -$176M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $54M Net Cash $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DNTH
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 83.5% (7th %ile) 0.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DNTH (3) vs RAPT (4)
Institutional Metric DNTH RAPT Criterion Row Edge
Market Capitalization
Scale
$5.2B $1.7B Larger Scale DNTH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+205.6% -100.0% Higher Growth DNTH
Operating Margin (TTM)
Profitability
-8683.9% 0.0% Higher Margin RAPT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-22.6% -85.4% Higher ROE DNTH
52-Week Range Position
Momentum
65% ($34–$118) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
1.04β · 41% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
$2.7M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($54M Net Cash) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNTH +2.88 pp
DNTH: +3.56% · RAPT: +0.68%
3M Horizon RAPT +48.93 pp
DNTH: +25.51% · RAPT: +74.44%
6M Horizon RAPT +66.67 pp
DNTH: +35.28% · RAPT: +101.95%
1Y Horizon RAPT +66.67 pp
DNTH: +35.28% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DNTH vs RAPT. Trailing 12-month operating profitability (DNTH -8683.9% vs RAPT 0.0%) and valuation multiples (DNTH N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DNTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.7M
Gross Margin100.0%
Op. Margin-8683.9%
ROE / Fwd P/E-22.6% · N/M
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DNTH CONSOLIDATION
149d in phase · OBV ACCUMULATION
Current IV 83.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DNTH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DNTH vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.75 (N/M Forward P/E, -8683.9% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. -100.0% YoY).

DNTH leads the Growth & Scale pillar: DNTH posts +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DNTH generates $2.7M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, DNTH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

DNTH and RAPT trade at balanced relative valuation multiples. DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNTH (-22.6% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 41% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.